We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KFFB:NASDAQKentucky First Federal Bancorp Analysis

Data as of 2026-05-19 - not real-time

$4.27

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Kentucky First Federal Bancorp is trading at $4.27, just below its 20‑day SMA of $4.39 and marginally above the identified support of $4.19, indicating limited upside in the near term. The RSI sits at 46, suggesting a neutral momentum environment, while the MACD histogram turned positive, offering a faint bullish signal. However, the stock exhibits extreme 30‑day volatility at over 60% and a very low beta of 0.06, meaning price swings are large but largely uncorrelated with the broader market. Volume has been increasing but remains thin (≈800 shares versus a 10‑day average of 4,460), raising liquidity concerns. Fundamentally, revenue surged 35% year‑over‑year, yet profitability is modest with a profit margin of 13% and ROE of only 2.9%. The price‑to‑earnings multiple of 25.1 dwarfs the regional bank industry average of 16.7, flagging the stock as overvalued despite a price‑to‑book ratio below 1.0. The company pays no dividend and recently announced the termination of an agreement with the OCC, a neutral operational event. Overall, the blend of high volatility, thin trading, and an elevated valuation tempers enthusiasm, while the strong revenue growth and low price‑to‑book provide a modest upside thesis for longer horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with limited upside
  • Extreme short‑term volatility
  • Thin trading volume increasing liquidity risk

Medium Term

1–3 years
Cautious
Model confidence: 5/10

Key Factors

  • PE ratio substantially above industry average
  • High sector headwinds for regional banks
  • Modest profitability and low ROE

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Strong revenue growth of 35% YoY
  • Price‑to‑book below 1 indicating value potential
  • Low beta suggesting limited market‑wide downside

Key Metrics & Analysis

Financial Health

Revenue Growth35.30%
Profit Margin12.94%
P/E Ratio25.1
ROE2.87%
ROA0.37%
P/B Ratio0.7
Industry P/E16.7

Technical Analysis

TrendNeutral
RSI46.0
Support$4.19
Resistance$4.67
MA 20$4.39
MA 50$4.46
MA 200$4.15
MACDBullish
VolumeIncreasing
Fear & Greed Index89.61

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.06
Volatility62.14%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.